Caspase involved synergistic cytotoxicity of bcl-2 antisense oligonucleotides and Adriamycin on transitional cell cancer cells

Cancer Letters

Volumn 155, Issue 2, 2000, Pages 191-198

  Bilim, Vladimir ^a   Kasahara, Takashi ^a   Noboru, Hara ^a   Takahashi, Kota ^a   Tomita, Yoshihiko ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Antisense oligonucleotides; Apoptosis; Bcl 2; Caspases; Transitional cell cancer

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE; DOXORUBICIN; PROTEIN BCL 2;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE;

EID: 0034738784     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00428-6     Document Type: Article

References (27)

1. D. Skinner G. Lieskovsky Diagnosis and Management of Genitourinary Cancers 1988 W.B. Saunders Philadelphia, PA
2. P. Carroll Urothelial carcinoma: cancers of the bladder, ureter, & renal pelvis E. Tanagho J. McAninch Smith's General Urology 1995 Appleton & Lange East Norwalk, CT 353 371
3. G.M. Mead M. Russell P. Clark S.J. Harland P.G. Harper R. Cowan J.T. Roberts B.M. Uscinska G.O. Griffiths M.K. Parmar A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party Br. J. Cancer 78 1998 1067 1075
4. V. Scattoni A. Bolognesi C. Cozzarini F. Francesca M. Grasso L. Galli T. Torelli B. Campo E. Villa P. Rigatti Neoadjuvant CMV chemotherapy plus radical cystectomy in locally advanced bladder cancer: the impact of pathologic response on long-term results Tumori 82 1996 463 469
5. V. Bilim Y. Tomita T. Kawasaki A. Katagiri T. Imai M. Takede K. Takahashi Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer (letter) J. Natl. Cancer Inst. 88 1996 686 688
6. V.N. Bilim Y. Tomita T. Kawasaki M. Takeda K. Takahashi Variable Bcl-2 phenotype in benign and malignant lesions of urothelium Cancer Lett. 128 1998 87 92
7. T. Kawasaki Y. Tomita R. Watanabe T. Tanikawa T. Kumanishi S. Sato mRNA and protein expression of p53 mutations in human bladder cancer cell lines Cancer Lett. 82 1994 113 121
8. R. Watanabe Y. Tomita T. Nishiyama T. Tanikawa S. Sato Correlation of p53 protein expression in human urothelial transitional cell cancers with malignant potential and patient survival Int. J. Urol. 1 1994 43 48
9. V. Bilim Y. Tomita T. Kawasaki M. Takeda K. Takahashi Adriamycin (ADM) induced apoptosis in transitional cell cancer (TCC) cell lines accompanied by p21 WAF1/CIP1 induction Apoptosis 2 1997 207 213
10. S. Kitada T. Miyashita S. Tanaka J.C. Reed Investigations of antisense oligonucleotides targeted against bcl-2 RNAs Antisense Res. Dev. 3 1993 157 169
11. A. Ziegler G.H. Luedke D. Fabbro K.H. Altmann R.A. Stahel U. Zangemeister-Wittke Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence (see comments) J. Natl. Cancer Inst. 89 1997 1027 1036
12. B. Jansen B. Brown BCL2 C.A. Stein A.M. Krieg Applied Antisense Oligonucleotide Technology, Chapter 17 1998 Wiley-Liss New York 317 334
13. U. Zangemeister-Wittke T. Schenker G.H. Luedke R.A. Stahel Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines Br. J. Cancer 78 1998 1035 1042
14. E. Schmitt A. Sane R. Bertrand Activation and role of caspases in chemotherapy-induced apoptosis Drug Resistance Updates 2 1999 21 29
15. C. Caulin G.S. Salvesen R.G. Oshima Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis J. Cell Biol. 138 1997 1379 1394
16. Z. Chen M. Naito T. Mashima T. Tsuruo Activation of actin-cleavable interleukin 1b-converting enzyme (ICE) family protease CPP-32 during chemotherapeutic agent-induced apoptosis in ovarian carcinoma cells Cancer Res. 56 1996 5224 5229
17. J. He C.M. Whitacre L.Y. Xue N.A. Berger N.L. Oleinick Protease activation and cleavage of poly(ADP-ribose) polymerase: an integral part of apoptosis in response to photodynamic treatment Cancer Res. 58 1998 940 946
18. E.A. Slee M.T. Harte R.M. Kluck B.B. Wolf C.A. Casiano D.D. Newmeyer H.G. Wang J.C. Reed D.W. Nicholson E.S. Alnemri D.R. Green Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner J. Cell Biol. 144 1999 281 292
19. T. Kawasaki Y. Tomita V. Bilim M. Takeda K. Takahashi T. Kumanishi Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations Int. J. Cancer 68 1996 501 505
20. Y. Tomita T. Kawasaki V. Bilim M. Takeda K. Takahashi Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1 (CD95)-mediated apoptosis in renal-cell-cancer cells Int. J. Cancer 68 1996 132 135
21. T. Mossmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays J. Immunol. Methods 65 1983 55 63
22. B. Drewinko T.L. Loo B. Brown J.A. Gottlieb E.J. Freireich Combinational chemotherapy in vitro with adriamycin. Observation of additive, antagonistic, and synergistic effects when used in two drug combinations on cultured human lymphoma cells Cancer Biochem. Biophys. 1 1976 187 195
23. Y. Gan M.G. Wientjes R.A. Badalament J.L. Au Pharmacodynamics of doxorubicin in human bladder tumors Clin. Cancer Res. 2 1996 1275 1283
24. C. Schulman E. Wespes C. Delcour J. Struyven Intra-arterial chemotherapy of infiltrative bladder carcinoma Eur. Urol. 11 1985 220 223
25. E.L. Arriola A.M. Rodriguez-Lopez J.A. Hickman C.M. Chresta Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis Oncogene 18 1999 1457 1464
26. T.W. Behrens D.L. Mueller Bcl-x and the regulation of survival in the immune system Immunol. Res. 16 1997 149 160
27. A. Webb D. Cunningham F. Cotter P.A. Clarke F. di Stefano P. Ross M. Corbo Z. Dziewanowska BCL-2 antisense therapy in patients with non-Hodgkin lymphoma Lancet 349 1997 1137 1141